Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor mutational burden is not predictive of cytotoxic chemotherapy response.

Oncoimmunology - 24 Jun 2020

Nikanjam Mina, Riviere Paul, Goodman Aaron, Barkauskas Donald A, Frampton Garrett, Kurzrock Razelle

Abstract excerpt

Background: High tumor mutational burden (TMB) predicts checkpoint blockade responsiveness, although the association with outcomes may be nuanced in certain tissue contexts. The correlation between TMB and cytotoxic chemotherapy sensitivity is unknown. This study evaluated the relationship between TMB and outcome in patients with solid tumors receiving cytotoxic chemotherapy. Methods: University of California San...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Gastrointestinal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 32923144
DOI: 10.1080/2162402X.2020.1781997
PMCID: PMC7458654

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Tumor mutational burden is not predictive of cytotoxic chemotherapy response.PMID 32923144Read ↗

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.Semantic proximity Read ↗

Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers.Semantic proximity Read ↗

High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse CancersSemantic proximity Read ↗

Tumor mutational burden in non-immunotherapy patients with heavily pretreated metastatic breast cancer: long-term outcomes from a single institution.Semantic proximity Read ↗

Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial.Semantic proximity Read ↗

Estimation of US Patients with Cancer who may Respond to Cytotoxic ChemotherapySemantic proximity Read ↗

Clinical Outcomes of Molecular Tumor Boards: A Systematic Review.Semantic proximity Read ↗

Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.